The company aims to revolutionize RNA therapeutics by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide-based therapies through its proprietary AOC platform. It invests in its platform, pipeline, and people to develop breakthrough therapies targeting genetic drivers of diseases.
